Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Assessing bioequivalence using genomic data.

Shein-Chung Chow1, Jun Shao, Li Li

  • 1National Health Research Institutes, Taiwan. schow@nhri.org.tw

Journal of Biopharmaceutical Statistics
|December 14, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deciphering the Functional Mechanisms of eIF3f in Tumors and Exploring Targeted Therapies.

Pharmacology research & perspectives·2026
Same author

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026
Same author

Inhibition of NHE1 induces trophoblast cell senescence via ADGRG6 mediated by CXCL8.

Journal of reproductive immunology·2026
Same author

Association Between Polymorphisms of 4 Common Genes and High Myopia Risk: A Comprehensive Analysis.

Medical science monitor : international medical journal of experimental and clinical research·2026
Same author

Neuroprotective effects of traditional Chinese medicine using zebrafish models - a review.

Frontiers in pharmacology·2026
Same author

FTO-modulated m<sup>6</sup>A demethylation and upregulation of KIF11 mRNA promotes retinal microvascular dysfunction in diabetic retinopathy.

Journal of translational medicine·2026
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

This study proposes a novel method to assess drug bioequivalence using genomic data, offering a potential alternative to traditional pharmacokinetic and dissolution profile analyses for generic drug approval.

Area of Science:

  • Pharmacogenomics
  • Drug Development
  • Regulatory Science

Background:

  • Bioequivalence assessment is crucial for generic drug approval, typically relying on drug absorption, pharmacokinetic data, or dissolution profiles.
  • Current methods may not fully capture inter-individual variability or predict clinical outcomes effectively.
  • The United States Food and Drug Administration allows dissolution profile similarity as a surrogate for bioequivalence in specific cases.

Purpose of the Study:

  • To propose a novel approach for assessing bioequivalence using genomic data.
  • To establish a framework for evaluating bioequivalence that accounts for potential biases and variations between genomic and pharmacokinetic data.
  • To extend the proposed methods to cover average, population, and individual bioequivalence.

Main Methods:

Related Experiment Videos

  • Utilizing genomic data collected from individuals to infer bioequivalence.
  • Developing a sensitivity analysis framework to address prediction bias between genomic and pharmacokinetic data.
  • Quantifying and managing variations differences between genomic and pharmacokinetic data within predefined limits.

Main Results:

  • The proposed methods provide a framework for assessing bioequivalence using genomic data.
  • Sensitivity analysis allows for the evaluation of prediction bias and variation differences.
  • The approach is adaptable for average, population, and individual bioequivalence assessments.

Conclusions:

  • Genomic data offers a promising surrogate for assessing drug bioequivalence.
  • The proposed sensitivity analysis method enhances the reliability of genomic-data-based bioequivalence assessment.
  • This approach could refine generic drug approval processes by incorporating pharmacogenomic insights.